Swedish protons
Protons. A step forward or perhaps only more expensive radiation therapy?
Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?
IAEA's role in the global management of cancer-focus on upgrading radiotherapy services
Steepness of the radiation dose-response curve for dose-per-fraction escalation keeping the number of fractions fixed
Dose-effect models for risk – relationship to cell survival parameters
Number of patients potentially eligible for proton therapy
Proton therapy of cancer: Potential clinical advantages and cost-effectiveness
The potential of proton beam radiation therapy in intracranial and ocular tumours
The potential of proton beam therapy in paediatric cancer
The potential of proton beam radiation therapy in head and neck cancer
The potential of proton beam radiation therapy in lung cancer (including mesothelioma)
The potential of proton beam radiation therapy in breast cancer
The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers
The potential of proton beam radiation therapy in gastrointestinal cancer
Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group
The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma
The potential of proton beam radiation for palliation and reirradiation
Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer
Kinase domain mutation of NTRK3 gene is uncommon in gastric carcinomas